Malaria with other antimalarials (known as artemisinin-combination therapy, or ACT), which decreases resistance to any single drug component. These additional antimalarials include: amodiaquine, lumefantrine, mefloquine or sulfadoxine/pyrimethamine. Another recommended combination is dihydroartemisinin and piperaquine. ACT is about 90% effective when used to treat uncomplicated malaria. To treat malaria during pregnancy, the WHO recommends the use of quinine plus clindamycin early in the pregnancy (1st trimester), and ACT in later stages (2nd and 3rd trimesters). In the 2000s (decade), malaria with partial resistance to artemisins emerged in Southeast Asia. Infection with "P. vivax", "P. ovale" or "P. malariae" usually do not require
Effects of parasitic worms on the immune system study, Dr. Hartgers "et al." drew a "cautious conclusion" that helminths make humans more susceptible to contracting malaria and experiencing some of its lighter symptoms, while actually protecting them from the worst symptoms. Hartgers reasons that a Th2-skewed immune system resulting from helminth infection would lower the immune system's ability to counter an initial malarial infection. However, it would also prevent a hyperimmune response resulting in severe inflammation, reducing morbidity and pathology. Effects of parasitic worms on the immune system The effects of parasitic worms, or helminths, on the immune system is a recently emerging topic of study among immunologists